Skip to main content

Table 3 Patient demographics

From: Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

  2019 (n = 518) 2020 (n = 441) (n2020n2019)/n2019 (%) p value
n % n %
Sex
 Male 467 90.15 402 91.16 13.92 0.596
 Female 51 9.85 39 8.84 23.53 0.596
Age
 < 50 26 5.02 24 5.44 7.69 0.769
 50–59 62 11.97 49 11.11 20.97 0.679
 60–69 164 31.66 152 34.47 7.32 0.357
 70–79 178 34.36 139 31.52 21.91 0.351
 ≥ 80 88 16.99 77 17.46 12.50 0.847
 Mean (SD)—years 68.8 (11.5) 68.6 (11.3)  
Socioeconomic status (IMD)
 Low 168 32.43 145 32.88 13.69 0.883
 Middle 170 32.82 143 32.43 15.88 0.897
 High 178 34.36 152 34.47 14.61 0.973
 Missing 2 0.39 1 0.23 50.00 0.660
Ethnicity
 White British 239 46.14 190 43.08 20.50 0.343
 White Other 26 5.02 28 6.35 − 7.69 0.373
 Black Caribbean 36 6.95 21 4.76 41.67 0.153
 Black African 17 3.28 19 4.31 − 11.76 0.405
 Black Other 4 0.77 5 1.13 − 25.00 0.563
 Asian 13 2.51 7 1.59 46.15 0.319
 Mixed 1 0.19 0 0.00 100.00 0.356
 Other 8 1.54 7 1.59 12.50 0.957
 Unknown 174 33.59 164 37.19 5.75 0.245
Performance status (ECOG)
 0 138 26.64 102 23.13 26.09 0.194
 1 323 62.36 204 46.26 36.84 < 0.0001*
 2 49 9.46 16 3.63 67.35 < 0.001*
 3 8 1.54 2 0.45 75.00 0.0357
 Missing 0 0.00 117 26.53 N.A < 0.0001*
  1. *Statistically significant p values after Bonferroni correction for multiple comparisons